A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein;

received anti-tumor therapy within 4 weeks prior to the first study treatment;

history of autoimmune disease;

history of other active malignancies within 3 years prior to the first treatment;